A 48-year-old man with a diagnosis of ulcerative colitis 18 years ago, under immunosuppressive treatment with azathioprine in the last 6 years due to corticosteroid dependence, was admitted to the Emergency Department due to fever of one week's evolution. Blood tests showed thrombocytopenia, CRP 96.9mg/L, ferritin 3021ng/mL and hypertriglyceridemia. Blood and urine cultures were negative. Viral serologies (hepatitis B and C, HIV, parvovirus, CMV, HSV), atypical bacteria (Borrelia, Chlamydia, Coxiella) and screening for latent tuberculosis were also negative. Thoracoabdominal CT scan only showed splenomegaly. The bone marrow aspirate revealed immature lymphoid cells and a hemophagocyte figure, fulfilling the criteria for hemophagocytic syndrome, starting corticosteroid therapy at a dose of 1mg/Kg. Subsequently, the existence of an intrasinusoidal CD3 + CD5- lymphoid infiltrate and a FISH study with isochromosome 7q was reported, a characteristic pattern of hepatosplenic T-cell lymphoma (HSTCL). The study was completed with liver biopsy appreciating a 70% infiltration of T lymphocytes (50% gamma-delta) therefore the diagnosis was confirmed. Chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide) was started with the aim of considering hematopoietic stem cell transplantation. Unfortunately, the patient died 6 months later.

Download full-text PDF

Source
http://dx.doi.org/10.17235/reed.2023.9472/2023DOI Listing

Publication Analysis

Top Keywords

hepatosplenic t-cell
8
t-cell lymphoma
8
lymphoma inflammatory
4
inflammatory bowel
4
bowel disease
4
disease 48-year-old
4
48-year-old man
4
man diagnosis
4
diagnosis ulcerative
4
ulcerative colitis
4

Similar Publications

Hepatosplenic T-cell lymphoma in children and adolescents.

Blood Adv

January 2025

Univeristy of Alabama at Birmingham, Birmingham, Alabama, United States.

Hepatosplenic T-cell lymphoma (HSTCL) is an aggressive mature T-cell lymphoma characterized by significant hepatosplenomegaly, bone marrow involvement, and minimal or no lymphadenopathy. Primarily affecting young adults, it is exceptionally rare in children and adolescents. This makes diagnosis and treatment particularly challenging for pathologists and pediatric oncologists.

View Article and Find Full Text PDF

Background: The detrimental effects of a high-fat diet (HFD) extend beyond metabolic consequences and include systemic chronic inflammation (SCI), immune dysregulation, and gut health disruption.

Objectives: In this study, we used Mendelian randomization (MR) to investigate the relationship between HFD, gut microbiota, and SCI.

Methods: Genetic variants associated with dietary fat were utilized to explore causal relationships.

View Article and Find Full Text PDF

Clinical and splenectomy-based treatment outcomes in 40 cases of hepatosplenic T-cell lymphoma: a comprehensive analysis.

World J Surg Oncol

December 2024

Department of Hematology, Huadong Hospital, Fudan University, No.221, Yan 'an West Road, Jing' an District, Shanghai, 200040, China.

Background/aim: This research study was conducted to examine the clinical characteristics and post-splenectomy survival outcomes of patients diagnosed with hepatosplenic T-cell lymphoma (HSTCL).

Materials And Methods: A total of 10 cases of HSTCL patients admitted to the Hematology Department of Fudan University Affiliated Huadong Hospital between January 2012 and December 2021 were included. In addition, we also included 30 other cases reported from domestic and international sources.

View Article and Find Full Text PDF
Article Synopsis
  • Toceranib phosphate is an approved treatment for canine mast cell tumors, but its long-term effectiveness for canine hepatosplenic T-cell lymphoma (HSTCL) has not been previously reported.
  • A 10-year-old dog presented with weight loss and other symptoms, leading to the discovery of HSTCL through various tests and surgeries, including a splenectomy and liver biopsy.
  • After starting toceranib treatment, the dog's liver enzyme levels decreased and it remained in good condition, demonstrating that toceranib may be a viable treatment option for HSTCL in dogs, with the dog surviving for 460 days post-treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!